$NTLA insider trading
Over the last 12 months, Intellia Therapeutics insiders reported 1 buy totaling $1.4M and 16 sales totaling $2.2M across SEC Form 4 filings. 18% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $1.4M 1 event
- Sold · 12m
- $2.2M 16 events
- Events · 12m
- 17 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 18% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | LEONARD JOHN MPresident and CEO · O·D | ▼ Sale | 22,675 | $12.65 | $287K | -1.9% | plan · 2 tranches |
| Jul 22, 2026 | Dulac Edward J IIIEVP, Chief Financial Officer · O | ▼ Sale | 8,111 | $11.25 | $91K | -5.2% | — |
| Jul 2, 2026 | Dulac Edward J IIIEVP, Chief Financial Officer · O | ▼ Sale | 4,677 | $18 | $84K | -2.9% | plan |
| Jul 1, 2026 | Dube Michael PVP, Chief Accounting Officer · O | ▼ Sale | 2,641 | $16.78 | $44K | -3.8% | — |
| Mar 2, 2026 | BASTA JAMESEVP, General Counsel · O | ▼ Sale | 1,211 | $13.78 | $17K | -0.8% | — |
| Mar 2, 2026 | Clark ElianaEVP, Chief Technical Officer · O | ▼ Sale | 607 | $13.78 | $8K | -0.6% | — |
| Jan 5, 2026 | LEONARD JOHN MPresident and CEO · O·D | ▼ Sale | 34,146 | $9.21 | $314K | -3.3% | — |
| Jan 5, 2026 | Schultes Birgit CEVP, Chief Scientific Officer · O | ▼ Sale | 8,508 | $9.21 | $78K | -7.9% | — |
| Jan 5, 2026 | BASTA JAMESEVP, General Counsel · O | ▼ Sale | 10,397 | $9.21 | $96K | -9.3% | — |
| Jan 5, 2026 | Cohen Fred ED | ▲ Buy | 150,000 | $9.35 | $1.4M | +261.1% | — |
| Jan 5, 2026 | Lebwohl DavidEVP, Chief Medical Officer · O | ▼ Sale | 11,903 | $9.21 | $110K | -8.9% | — |
| Jan 5, 2026 | Clark ElianaEVP, Chief Technical Officer · O | ▼ Sale | 9,515 | $9.21 | $88K | -9.8% | — |
| Jan 5, 2026 | Dulac Edward J IIIEVP, Chief Financial Officer · O | ▼ Sale | 6,379 | $9.21 | $59K | -6% | — |
| Jan 5, 2026 | Dube Michael PVP, Chief Accounting Officer · O | ▼ Sale | 2,989 | $9.21 | $28K | -5.4% | — |
| Dec 11, 2025 | LEONARD JOHN MPresident and CEO · O·D | ▼ Sale | 88,146 | $9.49 | $836K | -7.8% | plan · 3 tranches |
| Oct 1, 2025 | Schultes Birgit CEVP, Chief Scientific Officer · O | ▼ Sale | 31 | $17.38 | $539 | — | — |
| Oct 1, 2025 | Dube Michael PVP, Chief Accounting Officer · O | ▼ Sale | 1,871 | $17.38 | $33K | -3.3% | — |
| Aug 20, 2025 | CHASE WILLIAM JD | ▲ Buy | 100,000 | $10.03 | $1.0M | +288.2% | — |
Every $NTLA filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Intellia Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NTLA feed.